CYP2C19 and gastroesophageal reflux disease: The clinical influence of CYP2C19 genetic polymorphisms in the treatment of acid-related disorders where PPIs are required has been evidenced by different studies; for example, it has been shown that the treatment of EMs with GERD can fail when standard doses of PPIs are used independent of age [15–18].